KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Total Debt (2016 - 2025)

West Pharmaceutical Services' Total Debt history spans 17 years, with the latest figure at $202.8 million for Q4 2025.

  • For Q4 2025, Total Debt changed 0.1% year-over-year to $202.8 million; the TTM value through Dec 2025 reached $202.8 million, changed 0.1%, while the annual FY2025 figure was $202.8 million, 0.1% changed from the prior year.
  • Total Debt for Q4 2025 was $202.8 million at West Pharmaceutical Services, roughly flat from $202.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $254.6 million in Q1 2021 and bottomed at $72.8 million in Q4 2023.
  • The 5-year median for Total Debt is $204.8 million (2022), against an average of $192.9 million.
  • The largest YoY upside for Total Debt was 178.3% in 2024 against a maximum downside of 65.05% in 2024.
  • A 5-year view of Total Debt shows it stood at $253.0 million in 2021, then dropped by 18.3% to $206.7 million in 2022, then crashed by 64.78% to $72.8 million in 2023, then surged by 178.3% to $202.6 million in 2024, then increased by 0.1% to $202.8 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Total Debt are $202.8 million (Q4 2025), $202.7 million (Q3 2025), and $202.6 million (Q2 2025).